📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-26 16:57
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
USFDA Concludes Goa Formulation Facility Inspection With 5 Observations
The USFDA conducted an inspection of Unichem Laboratories' Goa formulation facility at Pilerne, Bardez, from September 21, 2026, to September 26, 2026. The inspection concluded with five observations, which the company stated are related to procedural enhancements. Unichem will submit its response to the regulator within the standard 15-day window. With the US market contributing around 64% of company revenue, the final classification of these observations remains critical.
Confidence: HIGH
What changedUSFDA completed an inspection of the Goa formulation site and issued 5 procedural observations.
Why it mattersThe US market drives roughly 64% of revenue; severe regulatory outcomes like Official Action Indicated (OAI) or warning letters could jeopardize approvals and product supplies.
Number of observations: 5Response timeline: 15 daysInspection dates: 21st September 2026 to 26th September 2026US revenue dependency: 64%
📅 Short termMarket may take a cautious stance until the company files its response within 15 days and clears regulatory concerns.
📈 Long termIf observations remain purely procedural and result in Voluntary Action Indicated (VAI), operational continuity and new ANDA commercialization will stay on track.
⚠ Risk flags
- US market revenue concentration at ~64%
- Risk of escalation to Warning Letter or Import Alert if remediation is deemed unsatisfactory by USFDA
Key Highlights
USFDA inspection conducted from September 21 to September 26, 2026
Inspection concluded with 5 observations related to procedural enhancements
Company to submit its formal response to the USFDA within 15 days
Goa Formulation facility is a key export site (US market accounts for 64% of overall revenue)
👀 What to Watch
Track the outcome of Unichem's 15-day response and the subsequent USFDA inspection classification (NAI, VAI, or OAI) to ensure no disruption to US supply or new product approvals.
Unichem Lab Faces GST Penalty of ₹87.07 Cr and Interest of ₹6.59 Cr in Appellate Order
Unichem Laboratories received an Order-In-Appeal from the Commissioner (Appeals Thane) upholding a GST penalty of ₹87.07 crore and interest liability of ₹6.59 crore (total demand of ~₹93.66 crore) relating to the cross charge of common services. The total disputed amount represents approximately 30.7% of the company's TTM net profit of ₹305 crore and 4.1% of TTM revenue. Unichem stated that it plans to file an appeal against the order within prescribed timelines and expects no material impact.
Confidence: HIGH
What changedThe Commissioner (Appeals Thane) rejected Unichem's appeal, sustaining a GST penalty of ₹87.07 crore and interest of ₹6.59 crore.
Why it mattersThe ₹93.66 crore demand is material relative to annual profitability, accounting for ~30.7% of TTM PAT, though the company plans to challenge the order.
Penalty amount: Rs. 87,07,09,556Interest liability: Rs. 6,58,76,590Total demand vs TTM PAT: ~30.7%Date of receipt of order: 18th September 2026 after 2.00 p.m.
📅 Short termNegative sentiment could weigh on the stock near term given the size of the demand (~₹93.66 crore), though no immediate operational disruption is expected.
📈 Long termLitigation could remain pending across appellate levels for several quarters; sustained adverse rulings would directly impact cash flows and profitability.
⚠ Risk flags
- Significant tax litigation exposure (₹93.66 cr)
- Potential requirement for mandatory pre-deposits to file next-stage appeals
Key Highlights
Received Order-In-Appeal on 18th September 2026 disallowing appeal for cross charge of common services
Penalty confirmed under Section 74(1) and 122(2)(b) of the CGST Act at Rs. 87,07,09,556
Interest liability demanded under Section 13 and Rule 47 at Rs. 6,58,76,590
Total exposure of Rs. 93.66 crore compared against TTM PAT of Rs. 305 crore (~30.7%)
Company intends to file an appeal before higher appellate forums based on legal advice
👀 What to Watch
Track the filing of the subsequent appeal before the Appellate Tribunal or High Court and monitor if any pre-deposit or cash outflow is mandated during litigation.
Unichem Q1 PAT at ₹41.47 Cr vs Loss YoY; Revenue Grows 20% to ₹632.62 Cr
Unichem Laboratories reported a strong turnaround in Q1 FY27, posting a consolidated net profit of ₹41.47 Cr compared to a net loss of ₹10.47 Cr in the same quarter last year. Revenue from operations grew 20.1% YoY to ₹632.62 Cr, representing approximately 28.7% of its TTM revenue. The improvement was driven by better cost management, with material costs falling to ₹190.02 Cr from ₹217.48 Cr YoY despite higher sales. The company continues to benefit from tax set-offs, resulting in a negligible current tax charge for the period.
Confidence: HIGH
What changedThe company has transitioned from a loss-making Q1 in the previous year to a profitable one, supported by double-digit revenue growth and significant reduction in raw material expenses.
Why it mattersThe turnaround indicates improved operational efficiency and better capacity utilization. Sustained profitability is crucial for the company to leverage its high promoter holding (70.2%) and low debt-to-equity ratio (0.02).
Q1 Revenue vs TTM Revenue: 28.7%Revenue from Operations: ₹632.62 CrNet Profit (PAT): ₹41.47 CrBasic EPS: ₹5.89YoY Revenue Growth: 20.1%
📅 Short termThe stock is likely to react positively in the short term due to the sharp turnaround in profitability and strong top-line growth exceeding the historical TTM run rate.
📈 Long termThe long-term outlook depends on the company's ability to navigate US generic pricing pressures and successfully integrate with Ipca's distribution network to drive the projected 18.3% growth rate.
⚠ Risk flags
- High dependency on the US market (64% of revenue)
- Pricing pressure in the US generics segment
- Regulatory risks from USFDA or EU authorities
Key Highlights
Revenue from operations increased 20.1% YoY to ₹632.62 Cr from ₹526.60 Cr.
Net profit turned positive at ₹41.47 Cr against a loss of ₹10.47 Cr in the year-ago period.
Basic EPS improved significantly to ₹5.89 from a negative ₹1.49 YoY.
Cost of materials consumed as a percentage of revenue dropped to 30% from 41.3% YoY.
Invested USD 80,000 (approx. ₹0.76 Cr) in its wholly-owned subsidiary, Unichem (China) Pvt Ltd.
👀 What to Watch
Investors should monitor the sustainability of these improved margins and the progress of the Ghaziabad and Goa plant ramp-ups. Key to long-term value will be the execution of synergies with the Ipca group and the commercialization of new ANDAs in the US market.
Unichem Lab FY26 Net Profit Jumps to ₹252.8 Cr; Q4 Revenue Dips to ₹575.1 Cr
Unichem Laboratories reported a consolidated net profit of ₹252.84 crore for FY26, a significant increase from ₹137.52 crore in FY25, largely driven by a one-time gain of ₹275.52 crore from the sale of its erstwhile registered office. However, Q4 FY26 performance showed weakness with revenue declining to ₹575.12 crore compared to ₹587.18 crore in the same period last year. The company also settled a major European Commission fine and interest totaling Euro 19.55 million. Management stability is ensured with the re-appointment of Mr. Pabitrakumar Bhattacharyya as MD & CEO for three years.
Key Highlights
FY26 Consolidated Revenue grew 4.3% YoY to ₹2,201.85 crore compared to ₹2,110.97 crore in FY25.
Full-year Net Profit rose to ₹252.84 crore, heavily bolstered by a ₹275.52 crore exceptional gain from property sale.
Q4 FY26 Net Profit fell sharply to ₹10.91 crore from ₹52.97 crore in Q4 FY25 due to higher other expenses and lower operational income.
Settled European Commission fine and interest aggregating to Euro 19.55 million during the year, with ₹58.26 crore interest recorded as an exceptional item.
MD & CEO Pabitrakumar Bhattacharyya re-appointed for a 3-year term starting August 2026.
👀 What to Watch
Investors should look past the headline profit growth as it is primarily driven by asset sales rather than core operations. Monitor the company's ability to stabilize margins and grow revenue in the pharmaceutical segment without the aid of one-time gains.
Unichem Laboratories Recalls Buspirone Hydrochloride Tablets in US Due to Quality Issues
Unichem Laboratories' wholly-owned US subsidiary has initiated a voluntary recall of Buspirone Hydrochloride Tablets (5 mg) in 500-count bottles. The recall was triggered by an out-of-specification (OOS) assay result identified during a 12-month long-term stability test. While the company has reported no adverse events to date, the recall highlights potential quality control risks in its US operations. Investors should monitor for any follow-up actions by the US FDA regarding the manufacturing site.
Key Highlights
Voluntary recall of Buspirone Hydrochloride Tablets (5 mg) in 500-count bottles in the USA market.
Recall initiated due to Out-of-specification (OOS) assay results at the 12-month stability time point.
No reports of adverse events related to this recall have been received by the company to date.
Action taken by Unichem Pharmaceuticals (USA), Inc., a 100% subsidiary of Unichem Laboratories.
👀 What to Watch
Investors should watch for any potential US FDA inspections or warning letters that might follow this quality lapse. While the immediate financial impact of one product recall is usually manageable, recurring quality issues can lead to higher compliance costs.
Unichem Shareholders Approve Director Appointment and Material Related Party Transactions
Unichem Laboratories has announced that shareholders have overwhelmingly approved three key resolutions via postal ballot with over 99.99% support for each. The resolutions included the appointment of Dr. Swati Patankar as an Independent Director for a five-year term and the approval of material related party transactions (RPTs). Specifically, transactions between the company, its holding company Ipca Laboratories, and its US subsidiary were cleared by non-promoter shareholders, ensuring operational continuity for its international business.
Key Highlights
Appointment of Dr. Swati Patankar as Independent Director approved with 99.999% votes in favor (5.67 crore votes).
Material related party transactions with holding company Ipca Laboratories approved by 99.992% of voting non-promoters.
Transactions with wholly-owned subsidiary Unichem USA received 99.992% support from voting shareholders.
Promoter group, holding 4.94 crore shares, abstained from voting on RPT resolutions due to being interested parties.
👀 What to Watch
The high approval rates for related party transactions suggest strong minority shareholder confidence in the company's governance and its strategic alignment with Ipca Laboratories. No immediate action is required as these are routine but necessary operational approvals.
Unichem Labs Proposes ₹2,000 Cr Related Party Transactions and New Independent Director
Unichem Laboratories has issued a postal ballot notice seeking shareholder approval for significant related party transactions (RPTs) for the 2026-27 fiscal year. The company is proposing a ₹1,600 crore limit for transactions with its US subsidiary and a ₹400 crore limit for transactions between its holding company, Ipca Laboratories, and the US subsidiary. Additionally, the company seeks to appoint Dr. Swati Patankar as a Non-Executive Independent Director for a five-year term. These approvals are essential for the company's continued operational integration with its parent and international subsidiaries.
Key Highlights
Proposed ₹1,600 crore limit for material related party transactions between Unichem and its US subsidiary for FY 2026-27.
Proposed ₹400 crore limit for transactions between holding company Ipca Laboratories and Unichem USA.
Appointment of Dr. Swati Patankar as a Non-Executive Independent Director for a 5-year term effective February 5, 2026.
E-voting period scheduled from February 26, 2026, to March 27, 2026.
Transactions include sale/purchase of goods, contract manufacturing, and product development charges at arm's length.
👀 What to Watch
Investors should monitor the execution of these high-value related party transactions to ensure they remain at arm's length and do not negatively impact minority shareholder interests. The scale of transactions indicates deep operational ties with Ipca Laboratories and a significant focus on the US market.
Unichem Labs Q3 PAT Surges to ₹264.29 Cr on ₹275.52 Cr Asset Sale Gain; New Director Appointed
Unichem Laboratories reported a significant jump in consolidated PAT to ₹264.29 crore for Q3 FY26, largely driven by a one-time exceptional gain of ₹275.52 crore from the sale of land and buildings. Revenue from operations remained relatively flat with a slight 2.2% YoY decline to ₹521.17 crore. The company successfully settled a long-standing European Commission fine, recording a related interest expense of ₹58.26 crore as an exceptional item during the nine-month period. Additionally, the board has strengthened its technical leadership by appointing Dr. Swati Patankar, an IIT Bombay professor with 35+ years of R&D experience, as an Independent Director.
Key Highlights
Consolidated PAT rose to ₹264.29 crore in Q3 FY26 from ₹57.85 crore YoY, primarily due to a ₹275.52 crore gain on disposal of assets.
Revenue from operations stood at ₹521.17 crore for the quarter, compared to ₹533.09 crore in the previous year's corresponding quarter.
Exceptional items for the nine-month period include a ₹58.26 crore interest charge for the settlement of a Euro 19.55 million EU fine.
Dr. Swati Patankar appointed as Non-Executive Independent Director for a 5-year term, bringing expertise in drug discovery and molecular microbiology.
Basic Earnings Per Share (EPS) for the quarter increased to ₹37.54 from ₹8.22 in the previous year.
👀 What to Watch
Investors should note that the profit surge is driven by non-recurring asset sales rather than core operational growth. However, the settlement of the EU fine removes a major regulatory overhang, and the new board appointment strengthens the company's R&D focus.
Unichem Lab Q3 PAT Surges to ₹264 Cr on Land Sale Gain; Operational Revenue Dips 2.2% YoY
Unichem Laboratories reported a massive surge in consolidated Net Profit to ₹264.29 crore for Q3 FY26, primarily driven by a one-time exceptional gain of ₹275.52 crore from the sale of its former registered office land and building. However, core operational performance was weak, with revenue from operations declining 2.2% YoY to ₹521.17 crore and profit before exceptional items falling sharply to ₹17.91 crore from ₹61.85 crore YoY. The company also fully settled a long-standing European Commission fine of Euro 19.55 million during the period. Additionally, the board has been reconstituted with the appointment of Dr. Swati Patankar as an Independent Director to bolster technical and R&D expertise.
Key Highlights
Consolidated Net Profit jumped to ₹264.29 Cr, heavily aided by a ₹275.52 Cr exceptional gain from land and building disposal.
Revenue from operations fell 2.2% YoY to ₹521.17 Cr and declined 10% on a sequential (QoQ) basis.
Profit before exceptional items and tax dropped significantly to ₹17.91 Cr compared to ₹61.85 Cr in the same quarter last year.
Settled European Commission fine and interest totaling Euro 19.55 million, with interest costs of ₹58.26 Cr recognized in the nine-month period.
Appointed Dr. Swati Patankar, a Professor at IIT Bombay, as a Non-Executive Independent Director for a 5-year term.
👀 What to Watch
Investors should discount the high bottom-line figure as it is driven by a one-time asset sale rather than business growth. Focus should remain on the declining operational margins and the impact of the finalized legal settlements in Europe.
Unichem Labs Kolhapur API Facility Receives 5 USFDA Observations; No Data Integrity Issues
The USFDA conducted an inspection at Unichem Laboratories' Kolhapur API facility from January 27 to February 2, 2026. The inspection concluded with five observations, which the company has characterized as procedural changes rather than critical failures. Importantly, the company confirmed that none of the observations pertain to data integrity, a common area of concern for regulators. Unichem is required to submit its formal response to the USFDA within 15 days to address these points.
Key Highlights
USFDA inspection conducted at Kolhapur API facility between Jan 27 and Feb 2, 2026
Inspection concluded with 5 observations related to procedural changes
Zero observations related to data integrity, reducing the risk of severe regulatory action
Company committed to providing a formal response to the USFDA within 15 days
👀 What to Watch
Investors should monitor the company's ability to resolve these procedural observations and wait for the final EIR (Establishment Inspection Report). While 5 observations require attention, the lack of data integrity issues suggests a lower risk of an Import Alert or Warning Letter.
Unichem Laboratories Recalls Two Products in US Market Due to Quality and Impurity Issues
Unichem Laboratories' US subsidiary has initiated a voluntary recall of two pharmaceutical products in the United States. The recall affects Doxazosin Tablets (4 mg) due to appearance defects and Bisoprolol Fumarate/Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) for exceeding N-Nitroso Bisoprolol impurity limits. While no adverse events have been reported to date, the recall highlights potential quality control challenges in the US supply chain. Investors should monitor for any subsequent US FDA actions or financial impact from these recalls.
Key Highlights
Voluntary recall of Doxazosin Tablets (4 mg, 1000 count) due to incorrect debossing on some tablets.
Recall of Bisoprolol Fumarate and Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) for exceeding N-Nitroso Bisoprolol impurity limits.
The recall was initiated by the company's wholly-owned subsidiary, Unichem Pharmaceuticals (USA), Inc.
No adverse events related to these recalls have been reported as of January 27, 2026.
👀 What to Watch
Investors should monitor the company's US sales performance in the coming quarters to assess the financial impact of these recalls. Watch for any further regulatory observations from the US FDA regarding manufacturing standards.
